Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can glucocorticoid treatment skew bone health tests? a study investigates

NCT ID NCT06395883

Knowledge-focused Sponsor: Diakonhjemmet Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study follows 160 people with inflammatory joint disease who are starting treatment with or without glucocorticoids, or receiving a glucocorticoid injection. Researchers will measure bone turnover markers (P1NP and CTX1) in blood samples every 4 weeks and up to 6 months after the last dose. The goal is to understand how these drugs affect bone marker levels, which are used to monitor osteoporosis treatment. This could help doctors interpret bone health tests more accurately in patients on glucocorticoids.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Glucocorticoid treatment (or no glucocorticoid treatment) as part of standard care for inflammatory joint disease
What this could lead to
If successful, this could improve how doctors monitor bone health in people taking glucocorticoids, potentially reducing fracture risk and optimizing osteoporosis care.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may vary due to differences in patients' conditions and treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a diagnosis of rheumatoid arthritis or spondyloarthritis or psoriatic arthritis

Ages

25 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * diagnosis of inflammatory rheumatic joint disease * indication of disease modifying treatment initiation with or without glucocorticoids OR * stable DMARD treatment with parenteral glucocorticoid injection Exclusion Criteria: * known osteoporosis or osteoporosis treatment * women during the transitory phase * oestrogen treatment * any fracture within the last year * chronic glucocorticoid treatment * glucocorticoid treatment within the last year prior to inclusion * active cancer * kidney failure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Inflammatory rheumatism are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

corticosteroid-induced osteoporosis glucocorticoid-induced osteoporosis osteoporosis rheumatic disorder rheumatic fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Inflammatory rheumatism Osteoporosis Osteoporosis, steroid induced

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Diakonhjemmet hospital

    RECRUITING

    Oslo, 0319, Norway

  • Vestre Viken HF, Drammen

    RECRUITING

    Drammen, 3024, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.